Takeda Cash And Equivalents vs Common Stock Analysis

TAK Stock

USD 13.46 0.28 2.04%

Takeda Pharmaceutical financial indicator trend analysis is much more than just breaking down Takeda Pharmaceutical prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Takeda Pharmaceutical is a good investment. Please check the relationship between Takeda Pharmaceutical Cash And Equivalents and its Common Stock accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Takeda Pharmaceutical Co. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

Cash And Equivalents vs Common Stock

Cash And Equivalents vs Common Stock Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Takeda Pharmaceutical Cash And Equivalents account and Common Stock. At this time, the significance of the direction appears to have strong relationship.

The correlation between Takeda Pharmaceutical's Cash And Equivalents and Common Stock is 0.62. Overlapping area represents the amount of variation of Cash And Equivalents that can explain the historical movement of Common Stock in the same time period over historical financial statements of Takeda Pharmaceutical Co, assuming nothing else is changed. The correlation between historical values of Takeda Pharmaceutical's Cash And Equivalents and Common Stock is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Cash And Equivalents of Takeda Pharmaceutical Co are associated (or correlated) with its Common Stock. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Common Stock has no effect on the direction of Cash And Equivalents i.e., Takeda Pharmaceutical's Cash And Equivalents and Common Stock go up and down completely randomly.

Correlation Coefficient

0.62

Relationship Direction	Positive
Relationship Strength	Significant

View All Relationships

Cash And Equivalents

Common Stock

Most indicators from Takeda Pharmaceutical's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Takeda Pharmaceutical current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Takeda Pharmaceutical Co. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

At this time, Takeda Pharmaceutical's Sales General And Administrative To Revenue is quite stable compared to the past year. Enterprise Value Over EBITDA is expected to rise to 18.12 this year, although the value of Selling General Administrative will most likely fall to about 783 B.

	2021	2022	2023	2024 (projected)
Interest Expense	166.6B	169.7B	119.5B	125.5B
Depreciation And Amortization	583.2B	664.4B	728.0B	764.4B

Interest Expense Depreciation And Amortization

Takeda Pharmaceutical fundamental ratios Correlations

	Total Assets	Common Stock Shares Outstanding	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Common Stock Total Equity	Short Term Investments	Non Current Liabilities Total	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Short Term Debt
Total Assets		-0.14	0.99	0.96	0.96	0.98	0.98	-0.08	0.98	-0.31	0.69	0.46	1.0	0.49	0.32	0.78	0.99	-0.58	0.98	0.98	0.87	0.85	0.99	0.9	0.91	0.58
Common Stock Shares Outstanding	-0.14		-0.05	-0.16	-0.07	-0.25	-0.29	-0.1	-0.03	-0.11	-0.14	0.16	-0.16	-0.49	0.08	0.06	-0.12	0.03	-0.04	-0.16	-0.46	-0.3	-0.05	-0.38	0.19	0.31
Short Long Term Debt Total	0.99	-0.05		0.92	0.96	0.94	0.95	-0.05	1.0	-0.35	0.68	0.46	0.99	0.46	0.31	0.79	0.99	-0.6	0.99	0.96	0.82	0.83	0.99	0.84	0.92	0.65
Other Current Liab	0.96	-0.16	0.92		0.93	0.96	0.96	-0.22	0.91	-0.35	0.67	0.48	0.96	0.45	0.32	0.68	0.95	-0.6	0.92	0.95	0.88	0.82	0.93	0.92	0.85	0.48
Total Current Liabilities	0.96	-0.07	0.96	0.93		0.92	0.93	-0.15	0.97	-0.33	0.74	0.38	0.96	0.39	0.2	0.75	0.95	-0.64	0.94	0.95	0.8	0.76	0.97	0.85	0.88	0.73
Total Stockholder Equity	0.98	-0.25	0.94	0.96	0.92		1.0	-0.18	0.93	-0.29	0.64	0.38	0.98	0.62	0.26	0.67	0.97	-0.54	0.92	0.99	0.94	0.91	0.93	0.97	0.83	0.49
Property Plant And Equipment Net	0.98	-0.29	0.95	0.96	0.93	1.0		-0.14	0.93	-0.31	0.68	0.38	0.98	0.61	0.25	0.69	0.97	-0.57	0.93	0.98	0.94	0.91	0.94	0.96	0.82	0.49
Current Deferred Revenue	-0.08	-0.1	-0.05	-0.22	-0.15	-0.18	-0.14		-0.05	0.14	-0.05	0.24	-0.09	-0.18	0.28	0.34	-0.05	0.14	0.04	-0.2	-0.16	-0.22	-0.01	-0.31	0.06	-0.27
Net Debt	0.98	-0.03	1.0	0.91	0.97	0.93	0.93	-0.05		-0.32	0.7	0.42	0.98	0.43	0.26	0.81	0.98	-0.59	0.99	0.95	0.8	0.8	0.99	0.82	0.92	0.68
Retained Earnings	-0.31	-0.11	-0.35	-0.35	-0.33	-0.29	-0.31	0.14	-0.32		-0.37	-0.33	-0.32	-0.02	-0.2	0.06	-0.38	0.44	-0.32	-0.32	-0.2	-0.4	-0.32	-0.31	-0.23	-0.18
Accounts Payable	0.69	-0.14	0.68	0.67	0.74	0.64	0.68	-0.05	0.7	-0.37		0.17	0.7	0.12	-0.02	0.57	0.68	-0.46	0.69	0.63	0.53	0.45	0.71	0.62	0.63	0.43
Cash	0.46	0.16	0.46	0.48	0.38	0.38	0.38	0.24	0.42	-0.33	0.17		0.44	-0.18	0.93	0.51	0.49	-0.34	0.53	0.37	0.2	0.24	0.5	0.26	0.63	0.08
Non Current Assets Total	1.0	-0.16	0.99	0.96	0.96	0.98	0.98	-0.09	0.98	-0.32	0.7	0.44		0.5	0.29	0.77	0.99	-0.59	0.98	0.98	0.88	0.86	0.98	0.91	0.89	0.57
Non Currrent Assets Other	0.49	-0.49	0.46	0.45	0.39	0.62	0.61	-0.18	0.43	-0.02	0.12	-0.18	0.5		-0.13	0.1	0.47	-0.11	0.38	0.61	0.78	0.81	0.39	0.68	0.22	0.15
Cash And Short Term Investments	0.32	0.08	0.31	0.32	0.2	0.26	0.25	0.28	0.26	-0.2	-0.02	0.93	0.29	-0.13		0.37	0.34	0.0	0.38	0.24	0.11	0.14	0.34	0.14	0.48	-0.09
Net Receivables	0.78	0.06	0.79	0.68	0.75	0.67	0.69	0.34	0.81	0.06	0.57	0.51	0.77	0.1	0.37		0.78	-0.4	0.85	0.67	0.53	0.42	0.83	0.51	0.88	0.46
Common Stock Total Equity	0.99	-0.12	0.99	0.95	0.95	0.97	0.97	-0.05	0.98	-0.38	0.68	0.49	0.99	0.47	0.34	0.78		-0.6	0.98	0.97	0.86	0.86	0.99	0.89	0.9	0.55
Short Term Investments	-0.58	0.03	-0.6	-0.6	-0.64	-0.54	-0.57	0.14	-0.59	0.44	-0.46	-0.34	-0.59	-0.11	0.0	-0.4	-0.6		-0.57	-0.56	-0.48	-0.53	-0.59	-0.52	-0.48	-0.51
Non Current Liabilities Total	0.98	-0.04	0.99	0.92	0.94	0.92	0.93	0.04	0.99	-0.32	0.69	0.53	0.98	0.38	0.38	0.85	0.98	-0.57		0.93	0.78	0.78	1.0	0.81	0.94	0.59
Inventory	0.98	-0.16	0.96	0.95	0.95	0.99	0.98	-0.2	0.95	-0.32	0.63	0.37	0.98	0.61	0.24	0.67	0.97	-0.56	0.93		0.91	0.91	0.95	0.94	0.85	0.59
Other Current Assets	0.87	-0.46	0.82	0.88	0.8	0.94	0.94	-0.16	0.8	-0.2	0.53	0.2	0.88	0.78	0.11	0.53	0.86	-0.48	0.78	0.91		0.92	0.8	0.96	0.65	0.33
Other Stockholder Equity	0.85	-0.3	0.83	0.82	0.76	0.91	0.91	-0.22	0.8	-0.4	0.45	0.24	0.86	0.81	0.14	0.42	0.86	-0.53	0.78	0.91	0.92		0.78	0.92	0.63	0.4
Total Liab	0.99	-0.05	0.99	0.93	0.97	0.93	0.94	-0.01	0.99	-0.32	0.71	0.5	0.98	0.39	0.34	0.83	0.99	-0.59	1.0	0.95	0.8	0.78		0.83	0.94	0.63
Property Plant And Equipment Gross	0.9	-0.38	0.84	0.92	0.85	0.97	0.96	-0.31	0.82	-0.31	0.62	0.26	0.91	0.68	0.14	0.51	0.89	-0.52	0.81	0.94	0.96	0.92	0.83		0.68	0.39
Total Current Assets	0.91	0.19	0.92	0.85	0.88	0.83	0.82	0.06	0.92	-0.23	0.63	0.63	0.89	0.22	0.48	0.88	0.9	-0.48	0.94	0.85	0.65	0.63	0.94	0.68		0.6
Short Term Debt	0.58	0.31	0.65	0.48	0.73	0.49	0.49	-0.27	0.68	-0.18	0.43	0.08	0.57	0.15	-0.09	0.46	0.55	-0.51	0.59	0.59	0.33	0.4	0.63	0.39	0.6

Click cells to compare fundamentals

Takeda Pharmaceutical Account Relationship Matchups

Takeda Pharmaceutical fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	12.8T	12.9T	13.2T	14.0T	15.1T	15.9T
Common Stock Shares Outstanding	1.6B	1.6B	1.6B	1.6B	1.6B	1.3B
Short Long Term Debt Total	5.1T	4.6T	4.3T	4.4T	5.5T	5.7T
Other Current Liab	682.3B	1.3T	1.4T	1.5T	1.4T	1.5T
Total Current Liabilities	2.2T	1.8T	2.1T	2.5T	2.3T	2.4T
Total Stockholder Equity	4.7T	5.2T	5.7T	6.4T	7.3T	7.6T
Property Plant And Equipment Net	1.4T	1.5T	1.6T	1.7T	2.0T	2.1T
Current Deferred Revenue	119.5B	588.0B	616.5B	109.9B	126.4B	120.1B
Net Debt	4.5T	3.7T	3.5T	3.8T	4.4T	4.6T
Retained Earnings	1.4T	1.5T	1.5T	1.5T	1.4T	1.4T
Accounts Payable	318.8B	232.1B	295.9B	307.5B	320.0B	187.0B
Cash	637.6B	966.2B	849.7B	533.5B	457.8B	587.6B
Non Current Assets Total	10.4T	10.2T	10.6T	11.6T	12.6T	13.2T
Non Currrent Assets Other	103.8B	100.3B	82.6B	63.3B	785.9B	825.1B
Cash And Short Term Investments	653.4B	1.0T	875B	553.7B	457.8B	722.1B
Net Receivables	784.9B	812.7B	724.4B	681.7B	612.4B	545.5B
Common Stock Total Equity	168.7B	1.6T	1.7T	1.7T	1.9T	2.0T
Short Term Investments	15.8B	36.6B	25.3B	20.2B	15.1B	14.3B
Liabilities And Stockholders Equity	12.8T	12.9T	13.2T	14.0T	15.1T	15.9T
Non Current Liabilities Total	5.9T	6.0T	5.3T	5.1T	5.5T	5.8T
Inventory	759.6B	753.9B	853.2B	986.5B	1.2T	1.3T
Other Current Assets	114.2B	180.1B	166.4B	196.3B	278.5B	292.4B
Other Stockholder Equity	1.6T	1.6T	1.6T	1.6T	4.2T	4.4T
Total Liab	8.1T	7.7T	7.5T	7.6T	7.8T	8.2T
Property Plant And Equipment Gross	1.4T	1.5T	2.5T	2.7T	3.2T	3.4T
Total Current Assets	2.5T	2.7T	2.6T	2.4T	2.6T	2.0T
Accumulated Other Comprehensive Income	92.6B	366.1B	934.2B	1.5T	2.5T	2.6T
Short Term Debt	586.8B	72.3B	257.9B	399.2B	433.5B	455.1B
Common Stock	1.7T	1.7T	1.7T	1.7T	1.7T	1.8T
Good Will	4.0T	4.0T	4.4T	4.8T	5.4T	5.7T
Intangible Assets	4.2T	3.9T	3.8T	4.3T	4.3T	2.3T
Other Assets	10.4T	454.1B	678.7B	429.3B	493.7B	469.0B
Other Liab	1.1T	831.0B	1.2T	544.1B	625.7B	713.1B
Net Tangible Assets	(3.8T)	(3.5T)	(2.8T)	(2.5T)	(2.3T)	(2.4T)
Long Term Debt	4.5T	4.6T	4.1T	4.0T	4.5T	3.1T
Long Term Investments	369.5B	348.4B	330.1B	378.9B	430.6B	305.1B
Short Long Term Debt	586.8B	22.2B	204.0B	339.6B	367.3B	335.6B
Treasury Stock	(74.4B)	(57.1B)	(87.5B)	(59.6B)	(53.6B)	(56.3B)
Property Plant Equipment	1.4T	1.5T	1.6T	1.7T	1.9T	1.1T
Long Term Debt Total	4.5T	4.6T	4.1T	4.0T	4.6T	3.3T

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

When determining whether Takeda Pharmaceutical is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Takeda Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Takeda Pharmaceutical Co Stock. Highlighted below are key reports to facilitate an investment decision about Takeda Pharmaceutical Co Stock:

How To Invest In Takeda

Details

Is Takeda Stock a good investment?

Details

What is Takeda Pharmaceutical's Net Worth?

Details

Largest Pharmaceuticals Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Takeda Pharmaceutical Co. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

You can also try the Content Syndication module to quickly integrate customizable finance content to your own investment portal.

Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Takeda Pharmaceutical. If investors know Takeda will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Takeda Pharmaceutical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

0.049

Dividend Share

192

Earnings Share

0.6

Revenue Per Share

1.4 K

Quarterly Revenue Growth

0.127

The market value of Takeda Pharmaceutical is measured differently than its book value, which is the value of Takeda that is recorded on the company's balance sheet. Investors also form their own opinion of Takeda Pharmaceutical's value that differs from its market value or its book value, called intrinsic value, which is Takeda Pharmaceutical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Takeda Pharmaceutical's market value can be influenced by many factors that don't directly affect Takeda Pharmaceutical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Takeda Pharmaceutical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Takeda Pharmaceutical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Takeda Pharmaceutical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Takeda Cash And Equivalents vs Common Stock Analysis

Cash And Equivalents vs Common Stock

Cash And Equivalents vs Common Stock Correlation Analysis

Correlation Coefficient

Cash And Equivalents

Common Stock

Takeda Pharmaceutical fundamental ratios Correlations

Takeda Pharmaceutical Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Takeda Pharmaceutical fundamental ratios Accounts

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Non Current Assets Total	+ 1.0	Total Assets
Net Debt	+ 1.0	Short Long Term Debt Total
Property Plant And Equipment Net	+ 1.0	Total Stockholder Equity
Total Liab	+ 1.0	Non Current Liabilities Total
Short Long Term Debt Total	+ 0.99	Total Assets
Common Stock Total Equity	+ 0.99	Total Assets

Short Term Investments	- 0.64	Total Current Liabilities
Short Term Investments	- 0.6	Common Stock Total Equity
Short Term Investments	- 0.6	Other Current Liab
Short Term Investments	- 0.6	Short Long Term Debt Total
Total Liab	- 0.59	Short Term Investments
Short Term Investments	- 0.59	Non Current Assets Total